Aug 30,2016

Taiwan-based Health2Sync gets $3M for diabetes management platform

Health2Sync, a Taiwanese diabetes management startup, has raised $3 million in a round led by WI Harper Group; with participation from Cherubic Ventures, iSeed Ventures, and SparkLabs Global Ventures. The investors are mostly firms with a presence in both Silicon Valley and in Asia. Funds will be used to expand the program outside of Taiwan and into surrounding markets, especially Japan.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 12,2016

Sanofi, Verily invest $500M in diabetes management joint venture Onduo

Verily Life Sciences , a division of Google parent company Alphabet, has teamed up with French healthcare company Sanofi to launch Onduo, a diabetes-focused collaboration that leverages Sanofi’s pharmaceutical expertise and Verily’s command of miniaturized electronics, analytics and consumer software development. The two companies together invested about $500 million in Onduo. The joint venture is based in Cambridge, Massachusetts and will combine a mix of devices, software, medicine and professional care to help people with diabetes manage their condition.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Sep 13,2016

Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform

In a move that will accelerate the overarching mission to make diabetes management easier worldwide, Glooko and Diasend today announced they will merge into a unified company. As a combined entity, the new company now serves 4000 diabetes clinics in 23 countries across 15 languages, impacting tens of millions of people with diabetes.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Sep 12,2016

Glooko and Diasend Merger Raise $8M

Two diabetes management companies, Mountain View, California-based Glooko and Gothenburg, Sweden-based Diasend, will merge into a unified company, leveraging the global capabilities of Diasend and the user-friendly platform of Glooko. The joint solution, which will operate under the Glooko name, will now serve 4,000 diabetes clinics in 23 countries across 15 languages.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Sep 14,2016

Lifescan, WellDoc finalize commercial partnership for diabetes management platform

The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies announced yesterday. Per the new agreement, the companies will integrate WellDoc’s FDA-cleared BlueStar diabetes management platform and mobile application with LifeScan’s OneTouch Verio Flex smartphone-connected blood glucose monitoring system.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 15,2016

MySugr adds premium coaching

Austria and San Diego-based mySugr has added coaching to the premium version of its mySugr Logbook app, the company announced this week. mySugr tapped diabetes educator Gary Schneider, author of the book 'Think Like a Pancreas', to lead a team of live 1-on-1 diabetes coaches who will work with users, drawing on their logged data as well as information they provide through unlimited in-app messaging. The coaching is only available to people who have already been using the app for a little while and have logged some data, and there are a limited number of sign-ups per week. If the service is full, users can be placed on a waiting list.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 28,2016

Abbott gets FDA clearance to bring FreeStyle Libre Pro CGM to US

Abbott has received FDA Clearance for its FreeStyle Libre Pro system, a key milestone in bringing the company's unique take on the continuous glucose monitor to the United States. In Europe, where the system has had CE Mark clearance since September 2014, there is both a prescription and over-the-counter version available and the latter is smartphone compatible.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 29,2016

Medtronic gets FDA nod for artificial pancreas system, preps to launch Watson-powered Sugar.IQ app

Medtronic came out with two pieces of news yesterday around its connected diabetes efforts: an FDA clearance for a hybrid closed loop insulin delivery system and the first test cohort of its Sugar.IQ app, created in collaboration with IBM Watson.

REGULATORY FDA

#closed loop

View Analyst & Ambassador Comments
Go to original news
Sep 01,2016

Weight loss efficacy of a novel mobile Diabetes Prevention Program delivery platform with human coaching

The main aim of this pilot study was to evaluate the weight loss efficacy of Noom's smartphone-based NDPP-based curricula with human coaching in a group of overweight and obese hyperglycemic adults receiving 16 weeks of core, plus postcore curriculum. In this study, it was hypothesized that the mobile DPP could produce transformative weight loss over time.

CLINICAL STUDY

#dtx

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 02,2016

Nemaura Medical Inc., sign Letter of Intent with Shenzen CAS Health Corp, for potential JV and manufacture of their sugarBEAT® system

Nemaura Medical Inc., a medical device company developing a minimally invasive, needle-free, wireless CGM patch known as sugarBEAT®, today announced that it has signed a letter of intent (LOI) with a Chinese Corporation, Shenzen CAS Health Corporation Limited, which is a partially owned subsidiary of the Chinese Academy of Science. The letter of intent covers three potential joint venture arrangements relating specifically to sugarBEAT® including (a) setting up a joint venture company to distribute in China, (b) setting up a manufacturing facility in China and (c) obtaining CFDA approval.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES